ARCHIVES

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

This article is from The Cancer Letter archive.

Vol. 13 No. 19 | May 8, 1987

Download PDF Visit The Full Archive

Related Articles

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

June 16, 1999

Tamoxifen Makes ER-Negative Breast Cancer Easier To Find

October 31, 2008

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

December 19, 1997

In Brief: Hammer Hears A Claim for The $1 Million Wynder’s Theory On Japan’s Colon Cancer Rates: Hamburgers

March 19, 1982

Cooperative Group Chairmen Told They Must Do Their Own Planning, Will Get Funds Increase

September 26, 1975

Estrogen Alone Didn’t Increase Lung Cancer Mortality In WHI

August 27, 2010